Literature DB >> 22047560

Host and pathogen factors for Clostridium difficile infection and colonization.

Vivian G Loo1, Anne-Marie Bourgault, Louise Poirier, François Lamothe, Sophie Michaud, Nathalie Turgeon, Baldwin Toye, Axelle Beaudoin, Eric H Frost, Rodica Gilca, Paul Brassard, Nandini Dendukuri, Claire Béliveau, Matthew Oughton, Ivan Brukner, Andre Dascal.   

Abstract

BACKGROUND: Clostridium difficile infection is the leading cause of health care-associated diarrhea, and the bacterium can also be carried asymptomatically. The objective of this study was to identify host and bacterial factors associated with health care-associated acquisition of C. difficile infection and colonization.
METHODS: We conducted a 15-month prospective study in six Canadian hospitals in Quebec and Ontario. Demographic information, known risk factors, potential confounding factors, and weekly stool samples or rectal swabs were collected. Pulsed-field gel electrophoresis (PFGE) was performed on C. difficile isolates to determine the genotype. Levels of serum antibodies against C. difficile toxins A and B were measured.
RESULTS: A total of 4143 patients were included in the study; 117 (2.8%) and 123 (3.0%) had health care-associated C. difficile infection and colonization, respectively. Older age and use of antibiotics and proton-pump inhibitors were significantly associated with health care-associated C. difficile infection. Hospitalization in the previous 2 months; use of chemotherapy, proton-pump inhibitors, and H(2) blockers; and antibodies against toxin B were associated with health care-associated C. difficile colonization. Among patients with health care-associated C. difficile infection and those with colonization, 62.7% and 36.1%, respectively, had the North American PFGE type 1 (NAP1) strain.
CONCLUSIONS: In this study, health care-associated C. difficile infection and colonization were differentially associated with defined host and pathogen variables. The NAP1 strain was predominant among patients with C. difficile infection, whereas asymptomatic patients were more likely to be colonized with other strains. (Funded by the Consortium de Recherche sur le Clostridium difficile.).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22047560     DOI: 10.1056/NEJMoa1012413

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  264 in total

1.  Overutilization of proton-pump inhibitors: what the clinician needs to know.

Authors:  Joel J Heidelbaugh; Andrea H Kim; Robert Chang; Paul C Walker
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

Review 2.  Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.

Authors:  Michael Kriss; Keith Z Hazleton; Nichole M Nusbacher; Casey G Martin; Catherine A Lozupone
Journal:  Curr Opin Microbiol       Date:  2018-07-20       Impact factor: 7.934

3.  Treatment of bacterial skin infections in ED observation units: factors influencing prescribing practice.

Authors:  John P Haran; Gregory Wu; Vanni Bucci; Andrew Fischer; Edward W Boyer; Patricia L Hibberd
Journal:  Am J Emerg Med       Date:  2015-08-21       Impact factor: 2.469

Review 4.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Clostridioides difficile Whole-genome Sequencing Differentiates Relapse With the Same Strain From Reinfection With a New Strain.

Authors:  Janice Cho; Scott Cunningham; Meng Pu; Ryan J Lennon; Jennifer Dens Higano; Patricio Jeraldo; Priya Sampathkumar; Samantha Shannon; Purna C Kashyap; Robin Patel
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

6.  Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.

Authors:  David M Faleck; Hojjat Salmasian; E Yoko Furuya; Elaine L Larson; Julian A Abrams; Daniel E Freedberg
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

7.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

8.  A novel subtyping assay for detection of Clostridium difficile virulence genes.

Authors:  Stephanie L Angione; Aartik A Sarma; Aleksey Novikov; Leah Seward; Jennifer H Fieber; Leonard A Mermel; Anubhav Tripathi
Journal:  J Mol Diagn       Date:  2014-01-13       Impact factor: 5.568

Review 9.  Host response to Clostridium difficile infection: Diagnostics and detection.

Authors:  Elena A Usacheva; Jian-P Jin; Lance R Peterson
Journal:  J Glob Antimicrob Resist       Date:  2016-09-20       Impact factor: 4.035

Review 10.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.